Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis
Clinical Gastroenterology and Hepatology · 2026-05 · 24 (5) · 1271-1279
DOI: 10.1016/j.cgh.2025.08.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Nicole Wolfset und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized, Food Hypersensitivity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regeneron Pharmaceuticals, Sanofi US.
Abstract (Originalsprache)
BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) is a chronic, type 2 inflammatory disease of the esophagus commonly triggered by food allergens. Eliminating dietary EoE trigger foods can effectively treat EoE in some cases, but maintaining adherence can be challenging and can reduce quality of life. We aimed to assess the efficacy of dupilumab on reintroducing these foods based on clinical outcomes in patients with EoE. METHODS: We conducted an open-label pilot study in which patients aged 6 to 25 years with EoE induced by milk, egg, soy, or wheat were treated with weight- and age-tiered dupilumab for 3 months, followed by standardized reintroduction of trigger foods at months 3, 6, and 9, while continuing on dupilumab treatment. Symptoms, histology, endoscopy, and esophageal diameter were compared prior to and following every phase of food reintroduction to month 12. All patients had previously failed trigger food reintroduction on their current EoE medication. RESULTS: Twenty-one patients were enrolled. All patients who completed the study were able to reintroduce at least one serving size of trigger foods by month 12, and 8 patients were able to add foods every 3 months. There was no worsening of any clinical outcome, including symptoms, histology, and esophageal diameter. There were no serious treatment-related adverse events. CONCLUSIONS: Patients with EoE treated with dupilumab were able to safely reintroduce EoE trigger foods into their diet without exacerbation of histologic, endoscopic, or symptomatic measures of EoE severity. Some patients were able to reintroduce food at an earlier timepoint than others. CLINICALTRIALS: gov, Number: NCT05247866.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
- Division of Gastroenterology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Sanofi, Morristown, New Jersey.
- Regeneron Pharmaceuticals Inc, Tarrytown, New York.
- Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electro…
Förderung
- Regeneron Pharmaceuticals
- Sanofi US
Zitieren
APA
Wolfset, N., Muir, A. B., Benitez, A. J., Williams, D., De La Torre, I., Ruffner, M. A., Hill, D. A., Cazeau, C., Angello, J. T., Radwan, A., Durrani, S., deMarchi, S., & Spergel, J. M. (2026). Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 24(5), 1271-1279. https://doi.org/10.1016/j.cgh.2025.08.025
Vancouver
Wolfset N, Muir AB, Benitez AJ, Williams D, De La Torre I, Ruffner MA, et al. Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology. 2026;24(5):1271-1279. doi:10.1016/j.cgh.2025.08.025
BibTeX
@article{Wolfset2026,
author = {Wolfset, Nicole and Muir, Amanda B and Benitez, Alain J and Williams, Danielle and De La Torre, Ignacio and Ruffner, Melanie A and Hill, David A and Cazeau, Christine and Angello, James T and Radwan, Amr and Durrani, Sandy and deMarchi, Sabina and Spergel, Jonathan M},
title = {Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {5},
pages = {1271--1279},
doi = {10.1016/j.cgh.2025.08.025}
}
EUVIMED